Real journeys and verified breakthroughs — updated regularly. See why patients from around the world are choosing China, and what's newly possible here.
A real estate businessman from São Paulo, Brazil, faced advanced gastric cancer with limited options at home. In April he travelled to a top-tier Grade AAA hospital in Shanghai, where he received bridging therapy followed by a CAR-T infusion. Within about three months, his tumour had shrunk significantly, and he has since returned to his normal life and work.
A real patient case shared with permission. Individual results vary and cannot be guaranteed.
For decades patients travelled East-to-West; today patients from the US, UK, Germany, France, Canada & New Zealand travel to China.
China's medical-tourism sector is projected to grow from ~US$1.3B (2025) to US$3.4B (2035), led by advanced cancer care.
China approved satri-cel — the world's first CAR-T cell therapy for a solid tumour (Claudin18.2+ advanced gastric cancer).
Shanghai-developed NEO became the first invasive BCI approved for use beyond clinical trials.
At Huashan Hospital (Fudan University), a man paralysed for 13 years regained mind-control of a computer within weeks.
A China-originated PD-1/VEGF bispecific became the first drug to beat pembrolizumab in Phase 3 lung cancer.
Shanghai recorded 300,000+ international medical-service visits in H1 2024 across 22 top hospitals.
Send us your case for a free, confidential review and a clear plan and quote — with no obligation, in your language.
You're not just another case to us — we treat every patient like family.
Free consultation · Reply within 24 hours · Fully confidential